BioCentury
ARTICLE | Company News

No right-to-try for BrainStorm's ALS therapy

June 26, 2018 1:38 PM UTC

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) will not make its NurOwn therapy available under the U.S. right-to-try law, it announced Tuesday.

NurOwn is in a Phase III trial to treat amyotrophic lateral sclerosis. It consists of autologous mesenchymal stromal cells induced to differentiate into neurotrophic factor-secreting cells...